Terms: = Prostate cancer AND TG, Thyroglobulin AND Clinical Outcome
4 results:
1. BRF1 accelerates prostate tumourigenesis and perturbs immune infiltration.
Loveridge CJ; Slater S; Campbell KJ; Nam NA; Knight J; Ahmad I; Hedley A; Lilla S; Repiscak P; Patel R; Salji M; Fleming J; Mitchell L; Nixon C; Strathdee D; Neilson M; Ntala C; Bryson S; Zanivan S; Edwards J; Robson CN; Goodyear CS; Blyth K; Leung HY
Oncogene; 2020 Feb; 39(8):1797-1806. PubMed ID: 31740786
[TBL] [Abstract] [Full Text] [Related]
2. Assessment of radiobiological metrics applied to patient-specific QA process of VMAT prostate treatments.
Clemente-Gutiérrez F; Pérez-Vara C; Clavo-Herranz MH; López-Carrizosa C; Pérez-Regadera J; Ibáñez-Villoslada C
J Appl Clin Med Phys; 2016 Mar; 17(2):341-367. PubMed ID: 27074458
[TBL] [Abstract] [Full Text] [Related]
3. ER stress drives Lipocalin 2 upregulation in prostate cancer cells in an NF-κB-dependent manner.
Mahadevan NR; Rodvold J; Almanza G; Pérez AF; Wheeler MC; Zanetti M
BMC Cancer; 2011 Jun; 11():229. PubMed ID: 21649922
[TBL] [Abstract] [Full Text] [Related]
4. Effect of SLCO1B3 haplotype on testosterone transport and clinical outcome in caucasian patients with androgen-independent prostatic cancer.
Hamada A; Sissung T; Price DK; Danesi R; Chau CH; Sharifi N; Venzon D; Maeda K; Nagao K; Sparreboom A; Mitsuya H; Dahut WL; Figg WD
Clin Cancer Res; 2008 Jun; 14(11):3312-8. PubMed ID: 18519758
[TBL] [Abstract] [Full Text] [Related]
